Pagina 1 di 2
HDACi: the Columbus's egg in improving cancer treatment and reducing neurotoxicity? III annualità
ANTHEM: AdvaNced Technologies for Human-centrEd Medicine
HDACi: then Columbus's egg in improving cancer treatment and reducing neurotoxicity? - II annualità
PNRR per la Missione 4, componente 2 Investimento 1.1- Avviso 104/2022 | Understanding and targeting CHEMOtherapy-related neuroTOXicity (CHEMOTOX)
Approccio olistico al soggetto fragile dopo il lockdown mediante interventi basati su ICT
HDACi: the Columbus's egg in improving cancer treatment and reducing neurotoxicity?
Multi-wavelength studies of the most massive nodes in the distant Cosmic Web
ARCH -AGE-RELATED CHANGES IN HEMATOPOIESIS
ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific agerelated hematological diseases (pediatric, adult, elderly), with… Leggi tutto the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 4 Partner organisations (2 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.
Identificazione di polimorfismi genici e alterazioni epigenetiche per lo sviluppo di nuovi approcci farmacologici nel trattamento della neuropatia da oxaliplatino in pazienti con carcinoma colorettale
Radiation-enhanced metal-based chemotherapy in the treatment of solid tumors - III annualità
Paginazione
- Pagina 1
- Pagina successiva